Loading provider…
Loading provider…
Hematology & Oncology Physician in Birmingham, AL
NPI: 1669734083Primary Employer
University of Alabama Health Services Foundation, PC.
uabmedicine.org
HQ Phone
Get Arnab's Phone Numberphone_androidMobile
Get Arnab's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardAL State Medical License
AL State Medical License
2019 - 2025
CA State Medical License
2016 - 2019
OH State Medical License
2015 - 2017

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Sinai Hospital of Baltimore
Residency • Internal Medicine
2012 - 2015
Medical College and Hospital Kolkata
Medical School
Until 2007
Johns Hopkins University
MPH • Epidemiology
—
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 171 | 315 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 65 | 103 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 56 | 56 |
Authors: Mehmet Bilen, Jodi Layton, Vadim Koshkin, Hamid Emamekhoo, Arpita Desai
Journal: Front Oncol
Publication Date: 2020-10-22
Authors: Rohit Bose, Christopher Hoimes, Mehmet Bilen, Ajjai Alva, Amanda Nizam, Matthew Campbell, Cameron Pywell, Deepak Kilari, Petros Grivas, Shilpi Gupta, Rafee Talukder, Cindy Jiang, Ali Khaki, Omar Alhalabi, Vadim Koshkin, Sumit Shah, Charles Nguyen, Hamid Emamekhoo, Yousef Zakharia
Journal: Eur Urol Oncol
Publication Date: 2024-12-20
Lead Sponsor: QED Therapeutics, Inc., a Bridgebio company
Collaborators: Helsinn Healthcare SA
Intervention / Treatment: DRUG: Placebo, DRUG: Infigratinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, OTHER: Pharmacological Study, PROCEDURE: Biospecimen Collection, OTHER: Clinical Observation, OTHER: Quality-of-Life Assessment, PROCEDURE: Computed Tomography, PROCEDURE: Cystoscopy, PROCEDURE: CT Urography
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: Canadian Cancer Trials Group
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, OTHER: Quality-of-Life Assessment, PROCEDURE: Nephrectomy, OTHER: Patient Observation